0 CHECKOUT

Leukemia Drug Pipeline Update

  • ID: 1197060
  • August 2016
  • Region: Global
  • Bioseeker
1 of 2

Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented.

There are today 456 companies plus partners developing 631 leukemia drugs in 913 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 164 drugs. Leukemia Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 333 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 319 out of the 323 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 70 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Drug Pipeline Update at a Glance

Investigators
Includes more than 456 principal companies plus their collaborators. READ MORE >

Note: Product cover images may vary from those shown
2 of 2



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
3 of 2
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Amgen Inc.
  • Quest Diagnostics, Inc.
  • Roche Diagnostics Ltd.
  • Clariant International Ltd
  • IGen Biotech SL
  • Abbott Laboratories Ltd.